Co-mutations in tumor immune microenvironment and immunotherapy

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

(2020) D. Marinelli et al.   ANNALS OF ONCOLOGY

Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma

(2019) Zhi-liang Wang et al.   Frontiers in Immunology

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity

(2018) Elise Alspach et al.   Cold Spring Harbor Perspectives in Biology

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

(2018) A Kron et al.   ANNALS OF ONCOLOGY

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

(2016) Yoon Jin Cha et al.   LUNG CANCER

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

(2015) A. Calles et al.   CLINICAL CANCER RESEARCH

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Expression of tumour-specific antigens underlies cancer immunoediting

(2012) Michel DuPage et al.   NATURE